Concerns regarding ipsilateral breast tumor recurrence (IBTR) and regional recurrence in patients with breast cancer with BRCA1 or BRCA2 pathogenic variants undergoing BCT still persist. This evidence concerns the gene BRCA2 and breast carcinoma.